Northrop Grumman Corp /DE/
NORTHROP GRUMMAN CORP /DE/
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$42.0B
Operating marginCalculated
10.8%
Net assets to total assetsCalculated
32.5%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★☆☆position among all companies
10.8%
Growth (revenue, 4-year average)
★★★☆☆position among all companies
4.1%
Capital efficiency
★★★★☆position among all companies
25.1%
Revenue and profit
Performance, financial position and capital allocation
Northrop Grumman Corp /DE/
Recent performance trends
Northrop Grumman Corp /DE/
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$35.7 billion | US$36.6 billion | US$39.3 billion | US$41.0 billion | US$42.0 billion |
| Operating income | US$5.7 billion | US$3.6 billion | US$2.5 billion | US$4.4 billion | US$4.5 billion |
| Net income | US$7.0 billion | US$4.9 billion | US$2.1 billion | US$4.2 billion | US$4.2 billion |
| Total assets | US$42.6 billion | US$43.8 billion | US$46.5 billion | US$49.4 billion | US$51.4 billion |
| Shareholders' equity | US$12.9 billion | US$15.3 billion | US$14.8 billion | US$15.3 billion | US$16.7 billion |
| Net cash provided by (used in) operating activities | US$3.6 billion | US$2.9 billion | US$3.9 billion | US$4.4 billion | US$4.8 billion |
| Net cash provided by (used in) investing activities | US$2.1 billion | US$-1.2 billion | US$-1.6 billion | US$-1.7 billion | US$-1.2 billion |
| Net cash provided by (used in) financing activities | US$-7.0 billion | US$-2.6 billion | US$-1.8 billion | US$-1.4 billion | US$-3.6 billion |
| Cash and cash equivalents | US$3.5 billion | US$2.6 billion | US$3.1 billion | US$4.4 billion | US$4.4 billion |
Revenue scale in the same industry
Northrop Grumman Corp /DE/
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/This companyFY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- 4 MedlineFY Dec 2025 US$28.4B
- … 39 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$1.4 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$4.4 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-3.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-1.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$4.8 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$1.5 billion | Consolidated | Disclosed |
| Dividends paid | US$1.3 billion | Consolidated | Disclosed |
| Net assets | US$16.7 billion | Consolidated | Disclosed |
| Net sales | US$42.0 billion | Consolidated | Disclosed |
| Operating income | US$4.5 billion | Consolidated | Disclosed |
| Net income | US$4.2 billion | Consolidated | Disclosed |
| Total assets | US$51.4 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$1.6 billion | Consolidated | Disclosed |
| Operating margin | 10.8% | Consolidated | Calculated |
| Net assets to total assets | 32.5% | Consolidated | Calculated |
| Net margin | 10.0% | Consolidated | Calculated |
| Return on equity | 25.1% | Consolidated | Calculated |